Idera Pharmaceuticals Announces Presentation at 2nd Annual Cancer Immunotherapy Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, (Nasdaq: IDRA) a biopharmaceutical company developing therapeutics targeting Toll-like Receptors (TLRs) and advancing gene-silencing oligonucleotide (GSO) technology, today announced that Sudhir Agrawal, D.Phil, Chairman and Chief Executive Officer, is scheduled to present at the MD Becker Partners Cancer Immunotherapy: A Long-Awaited Reality in New York City on Thursday, October 6th. Dr. Agrawal will present a corporate overview at 9:15 am ET. The corporate overview will be available as a live audio webcast.

Dr. Agrawal will also take part in an expert panel entitled “Adjuvants in Immunotherapy” from 10:30-11:30 am ET, highlighting Idera’s TLR3, 7, 8 and 9 agonists for use as vaccine adjuvants and for immunotherapy in oncology.

A live audio webcast of the corporate presentation will be available in the Investor section of Idera’s website: www.iderapharma.com. An archived version will also be available on the Company’s website for a limited time after the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Idera

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Additionally, the company is advancing gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.



CONTACT:

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
[email protected]
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
[email protected]

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.